What is the role of idarucizumab in the treatment of hereditary and acquired hypercoagulability?

Updated: Jan 05, 2018
  • Author: Paul Schick, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print

There has been progress in developing antidotes to direct thrombin and factor Xa inhibitors. [55] Idarucizumab, a humanized monoclonal antibody that binds to and inactivates dabigatran, has received expedited approval from the US Food and Drug Administration (FDA).

Andexanet alfa is a genetically engineered factor Xa molecule that has no procoagulant activity but can bind with and neutralize both direct factor Xa inhibitors (eg, rivaroxaban, apixaban, edoxaban) and the factor Xa inhibitors that act through antithrombin (LMWHs and fondaparinux). A phase 3b–4 study of andexanet for treatment of acute major bleeding in patients receiving a factor Xa inhibitor is currently recruiting participants.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!